NABILONE-DEA SCHEDULE II
|
|
- CAS-Nr.
- 51022-71-0
- Englisch Name:
- NABILONE-DEA SCHEDULE II
- Synonyma:
- Nabilone;lilly109514;Nabilone solution;trans-(+-)-hydroxy-;NABILONE-DEA SCHEDULE II;d)pyran-9-one,3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-9h-dibenzo(;(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydrobenzo[c]chromen-9-one;trans-6,6-Dimethyl-3-(1,1-dimethylheptyl)-1-hydroxy-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one;9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-;NabiloneQ: What is
Nabilone Q: What is the CAS Number of
Nabilone Q: What is the storage condition of
Nabilone Q: What are the applications of
Nabilone
- CBNumber:
- CB4504001
- Summenformel:
- C24H36O3
- Molgewicht:
- 372.54
- MOL-Datei:
- 51022-71-0.mol
|
NABILONE-DEA SCHEDULE II Eigenschaften
- Schmelzpunkt:
- 155-156°C
- Siedepunkt:
- 457.4±45.0 °C(Predicted)
- Dichte
- 1.029±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- L?slichkeit
- DMSO: ~18 mg/mL, soluble
- Aggregatzustand
- solid
- pka
- pKa in 66% DMF: 13.5(at 25℃)
- Farbe
- white
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
H336 |
Kann Schl?frigkeit und Benommenheit verursachen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Schl?frigkeit und Benommenheit) |
Warnung |
|
P261, P271, P304+P340, P312,P403+P233, P405, P501 |
H361 |
Kann vermutlich die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. |
Reproduktionstoxizit?t |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
|
Sicherheit |
P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
P261 |
Einatmen von Staub vermeiden. |
P264 |
Nach Gebrauch gründlich waschen. |
P264 |
Nach Gebrauch gründlich waschen. |
P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
P308+P313 |
BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
|
NABILONE-DEA SCHEDULE II Chemische Eigenschaften,Einsatz,Produktion Methoden
R-S?tze Betriebsanweisung:
R22:Gesundheitssch?dlich beim Verschlucken.
S-S?tze Betriebsanweisung:
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn m?glich, dieses Etikett vorzeigen).
Chemische Eigenschaften
White to Off-White Solid
Verwenden
A labelled synthetic cannabinoid with antiemetic, antiglaucoma, and CNS activity. Antiemetic.
Controlled substance (hallucinogen).
Weltgesundheitsorganisation (WHO)
Nabilone is a structural analogue of dronabinol (delta-9-
tetrahydrocannabinol), the major active component of cannabis.
Pharmakologie
Nabilone is a synthetic analogue of THC that has shown particular promise in laboratory models of CUD. Nabilone has better bioavailability, a longer duration of action, and lower abuse liability than dronabinol, and since it produces unique urinary metabolites, researchers can distinguish cannabis use from medication compliance. Haney et al. investigated two doses of nabilone in the human laboratory and showed that this medication significantly decreased a laboratory measure of cannabis relapse and improved mood symptoms of withdrawal, such as irritability. Further, the higher nabilone dose also decreased craving for cannabis, increased quality of sleep, and improved food intake. In 2016, Herrmann et al. used a similar human laboratory design to test the combination of nabilone and the GABAA agonist, zolpidem, hypothesizing that combining nabilone with an efficacious sleep medication may produce more robust reductions in cannabis withdrawal and relapse than those observed with nabilone alone by Haney et al. Zolpidem was also tested alone, and although it improved sleep during cannabis withdrawal relative to placebo, it did not reduce relapse. The combination of zolpidem and nabilone provided a more comprehensive reduction in withdrawal symptoms (negative mood, anorexia, disrupted sleep) and also reduced cannabis relapse. The authors suggest that the majority of these effects are attributable to nabilone. These laboratory findings await confirmation in clinical treatment settings, but the results of these studies demonstrate that nabilone holds considerable promise for CUD treatment.
NABILONE-DEA SCHEDULE II Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
51022-71-0()Verwandte Suche:
- NABILONE-DEA SCHEDULE II
- d)pyran-9-one,3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-9h-dibenzo(
- lilly109514
- trans-(+-)-hydroxy-
- Nabilone
- trans-6,6-Dimethyl-3-(1,1-dimethylheptyl)-1-hydroxy-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one
- Nabilone solution
- (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydrobenzo[c]chromen-9-one
- 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-
- NabiloneQ: What is
Nabilone Q: What is the CAS Number of
Nabilone Q: What is the storage condition of
Nabilone Q: What are the applications of
Nabilone
- 51022-71-0
- Chiral Reagents
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Isotope Labelled Compounds